AVID CHEMOTHERAPEUTICS Is focused on the development of a targeted carbon-based nanoparticle therapeutic for the treatment of cancers using the company’s proprietary class of nanovectors for the combined targeted delivery of insoluble chemotherapeutic drugs and a drug pump inhibitor into tumors.
Avid’s lead molecule, vinblastine/indomethacin/PepEGFR-PEG-HCC, uses an EGFR targeting peptide attached to the PEG-HCC to target tumors that overexpress the EGF receptor and carry the insoluble FDA-approved chemotherapy drug vinblastine, and indomethacin, a drug pump inhibitor. Avid’s PEG-HCCs are a novel, modular drug delivery technology with several advantages, including the ability to adjust the covalently bound targeting moiety, flexibility in the choice of drug cargo, and the ability to deliver multiple drugs in a single dose. Further, the technology addresses some of the issues with current chemotherapy including:
> Challenges with solubilizing and delivering novel hydrophobic chemotherapeutic agents
> Limited ability to specifically target tumors and off-target systemic toxicity
> Development of chemotherapy resistance
Avid’s initial focus is on GBM, the most common and aggressive primary brain tumor in humans with median survival of only 15 months. Vinblastine /indomethacin / PepEGFR-PEGHCC is being developed as a treatment for the nearly 11,000 adults newly diagnosed with GBM per year. Currently, these patients have limited therapeutic options and even modest improvements in survival in this orphan-designated disease would lead to timely acceptance by physicians and patients into the GBM treatment market. Our point of entry into the market will be patients with recurrent, EGFR-positive disease.